Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petra Huber

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
International Journal of Cancer|May 2, 2026
Combination of Lenvatinib and Antibiotics: A Potential Approach to Enhance Sensitivity in Differentiated Thyroid CancerCelina Ablinger, Petra Huber-Cantonati, Daniela D Weber, et al.
Oncogene|October 9, 2019
A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastomaStefan Salcher, Gilles Spoden, Judith Hagenbuchner, et al.
Metabolites|February 25, 2022
Analogues of Natural Chalcones as Efficient Inhibitors of AKR1C3Gabriele Möller, Veronika Temml, Antonio Cala Peralta, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 12, 2020
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinomaMartina Meßner, Sabine Schmitt, Maximilian A Ardelt, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
International Journal of Cancer|May 2, 2026
Combination of Lenvatinib and Antibiotics: A Potential Approach to Enhance Sensitivity in Differentiated Thyroid CancerCelina Ablinger, Petra Huber-Cantonati, Daniela D Weber, et al.
Oncogene|October 9, 2019
A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastomaStefan Salcher, Gilles Spoden, Judith Hagenbuchner, et al.
Metabolites|February 25, 2022
Analogues of Natural Chalcones as Efficient Inhibitors of AKR1C3Gabriele Möller, Veronika Temml, Antonio Cala Peralta, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 12, 2020
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinomaMartina Meßner, Sabine Schmitt, Maximilian A Ardelt, et al.
Pageof 2